Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
L. acidophilus vs L. rhamnosus GG: L. rhamnosus GG has the stronger overall evidence (6 vs 5/10); they're alternatives for improve digestion — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
L. rhamnosus GG wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
1-100 billion CFU (10^9 to 10^11) per serving — the range FDA reviewed without objection for L. acidophilus DDS-1 in foods generally (GRAS Notice GRN 871); La-14 was noticed at 1 billion CFU per 250 g serving (GRN 502)
any
A product naming its strain (e.g. NCFM, DDS-1, La-14, La-5)
10-20 billion CFU (1-2 x 10^10) daily; 10 billion CFU/day is the effective floor
any
Capsule standardized to ATCC 53103
Weeks
Weeks
Course of antibiotics
During the antibiotic course
During hospital stay
n/a
n/a
Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.
Nutrients (2020) · Rct
Multicentre randomised controlled trial in irritable bowel syndrome (PubMed publication types: Randomized Controlled Trial, Multicenter Study)
The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial.
Nutr J (2016) · Crossover
Randomised, double-blind, placebo-controlled crossover trial (PubMed publication types: Randomized Controlled Trial)
Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial.
Lancet (2013) · Rct
Randomised, double-blind, placebo-controlled multicentre trial in inpatients aged 65 and over (PubMed publication types: Randomized Controlled Trial, Multicenter Study)
Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children.
N Engl J Med (2018) · Rct · n=971
Primary outcome (modified Vesikari score >=9 within 14 days): 11.8% with LGG vs 12.6% placebo; RR 0.96 (0.68-1.35), P=0.83
Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults.
Aliment Pharmacol Ther (2015) · Meta analysis
Antibiotic-associated diarrhea fell from 22.4% to 12.3%; RR 0.49 (0.29-0.83) pooled across 11 RCTs, n=1,308 (12 RCTs, n=1,499 included overall)
Probiotics for treating acute infectious diarrhoea.
Cochrane Database Syst Rev (2020) · Meta analysis
In studies at low risk of bias, no difference in diarrhea lasting >=48 hours (RR 1.00, 0.91-1.09; moderate certainty)
L. rhamnosus GG has a higher evidence score (6/10 vs 5/10) and wins in 2 of 3 categories.
For improve digestion, L. rhamnosus GG has a higher relevance score (72 vs 55).
No known interactions between L. acidophilus and L. rhamnosus GG have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.